↓ Skip to main content

Dove Medical Press

Article Metrics

Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated falciparum malaria in pregnancy: a randomized…

Overview of attention for article published in Clinical Pharmacology : Advances and Applications, May 2017
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#49 of 104)
  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
13 Mendeley
Title
Comparative analysis of the safety and tolerability of fixed-dose artesunate/amodiaquine versus artemether/lumefantrine combinations for uncomplicated <em>falciparum</em> malaria in pregnancy: a randomized open label study
Published in
Clinical Pharmacology : Advances and Applications, May 2017
DOI 10.2147/cpaa.s131351
Pubmed ID
Authors

Osede I Iribhogbe, Igue Emmanuel, Marylove Odianosen, Osede Iribhogbe

Abstract

A comparative clinical study was conducted to evaluate the safety and tolerability of two commonly used fixed dose artemisinin-based combinations for the treatment of uncomplicated Plasmodium falciparum malaria in the second and third trimester of pregnancy. To achieve this, a total of 155 participants were recruited for the study. Eighty of these were drawn from pregnant women who came for routine antenatal care while 40 nonpregnant participants were recruited from apparently healthy females in the community. Eighty pregnant participants with uncomplicated P. falciparum malaria were randomized into artesunate/amodiaquine (AA) and artemether/lumefantrine (AL) treatment arms while 40 nonpregnant and 35 nonmalarious pregnant women were used as control. The interventional groups received standard fixed dose combinations of AA (100/270 mg) daily or AL (20/120 mg) twice daily for 3 days. Blood samples were collected on day 4 and patients were followed-up closely to ascertain the safety of the drugs. The study showed a significant (p<0.0001) elevation of alkaline phosphatase in the AA and AL group compared to the nonpregnant control and a significant (p<0.05) elevation of alanine transaminase and aspartate transaminase level in the AL combination group when compared with the AA group. The elevated hepatic enzymes were within the normal range for pregnancy and were not clinically significant. Adverse event rate was higher in the AA group (n=28 [70%]) when compared to the AL group (n=4 [10%]) although the drugs were well-tolerated in both treatment arms. In conclusion, the use of these combinations is safe in the second and third trimester of pregnancy. However, we recommend active pharmacovigilance and spontaneous drug reporting of the agents in order to continuously monitor safety in the vastly heterogeneous population.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 31%
Student > Ph. D. Student 3 23%
Lecturer 1 8%
Student > Doctoral Student 1 8%
Student > Postgraduate 1 8%
Other 0 0%
Unknown 3 23%
Readers by discipline Count As %
Medicine and Dentistry 3 23%
Biochemistry, Genetics and Molecular Biology 2 15%
Agricultural and Biological Sciences 1 8%
Nursing and Health Professions 1 8%
Physics and Astronomy 1 8%
Other 2 15%
Unknown 3 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2017.
All research outputs
#6,028,706
of 10,867,257 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#49
of 104 outputs
Outputs of similar age
#125,906
of 264,984 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 2 outputs
Altmetric has tracked 10,867,257 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 104 research outputs from this source. They receive a mean Attention Score of 2.8. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,984 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.